Stock·NYSE·Energy
Devon Energy Corporation (DVN)
- Market cap
- $55.80B
- P/E
- 10.80
- Dividend yield
- 2.21%
- Street target
- $62.00median of 28 analysts
- 52-week range
- $31.47 $52.71
The short version
Where DVN stands today, in four lines, and what CleaRank Financial AI makes of it.
DVN at a glance
Devon Energy Corporation (DVN): Strong Buy, 87/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($47.96 and $45.24).
- Earnings DVN beat estimates in 3 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $5.9M and bought $200K over the last 18 months.
- Valuation P/E of 10.8 against 18.4 for the Energy sector: a discount to peers (-41%).
Figures as of October 16, 2026.
CleaRank Financial AI
CleaRank rates Devon Energy Corporation (DVN) Strong Buy, with a model score of 87/100.
The trend lifts the score most: the price is 12.13% above its 200-day average and 5.78% above its 50-day average, and the 50-day average is 6.01% above the 200-day. The 50-day average stands at $47.96 and the 200-day at $45.24. Over the past year the price rose 58.38%.
Only on CleaRank
Figures we compute ourselves from DVN's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $50.73 is 5.8% above the 50-day simple moving average of $47.96.Price above its 200-day average ›
The price is 12.1% above the 200-day simple moving average of $45.24.50-day average above the 200-day ›
The 50-day average ($47.96) is 6.0% above the 200-day average ($45.24), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 91% of its 52-week range, between $31.47 and $52.71.
DVN share price
Pick a period: each tab shows how far DVN has moved over it, to the last close.
Today's trading
Where DVN sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 10.80 is 41.3% below the Energy median of 18.4.P/S below the sector median ›
The price-to-sales ratio of 2.88 is 15.4% above the sector median of 2.5.Profitable over the last 12 months ›
Net income over the last 12 months was $3.3B on revenue of $18.8B, a net margin of 17.5%.Beat estimates in most recent reports ›
DVN beat the EPS estimate in 3 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 2.21%, or $1.12 a share a year.
Key statistics
The headline figures for DVN.
As of October 16, 2026, DVN trades at $50.73, with a market value of $55.80B, a P/E ratio of 10.80 and a dividend yield of 2.21%.
What the numbers say
CleaRank Financial AI's reading of DVN's valuation, growth and risks.
DVN's trailing P/E of 10.80 is 41.3% below the Energy sector median P/E of 18.4, a level the Peer Benchmarking card describes as a discount to peers. On sales, the stock trades at 2.88 times, which is 15.2% above the sector median P/S of 2.5. Its market capitalisation stands at $55.8B.
With revenue growth of 64.20%, DVN is 31.4 percentage points faster than the sector median of 32.8%. DVN turns sales into profit at a net margin of 17.46% and an operating margin of 41.08%, alongside a return on equity of 11.52%, below the sector median of 14.2%. The balance sheet and payout round out the picture, with debt-to-equity of 0.28 and a trailing dividend yield of 2.21% ($1.12 a share a year).
DVN beat estimates with EPS of $1.57 against a forecast of $1.41 for the August 4, 2026 report, a beat of 11.35%. The share price nonetheless dropped 4.45% in the first session after the report.
Over its last 7 reports, DVN topped the estimate 3 times, but beats have not guaranteed gains: the stock fell the next day after 1 of them. The May 5, 2026 report stands out among the earlier ones: a miss of 4.59%, after which the stock fell 8.61%. The consensus EPS estimate stands at $5.42 for this fiscal year and $5.00 for next, growth of 38.2% for the current year.
DVN's daily returns have a 30-day standard deviation of 1.99%. Over the last 18 months, insiders sold $5.9M of stock and bought $200K. Insider sales are often planned in advance or made to cover taxes on vesting shares, so they carry less weight than open-market purchases.
DVN against the Energy sector
How DVN compares with the median Energy stock CleaRank tracks.
Price to earnings vs sector: DVN trades at a notable discount to sector peers (-41%), which may indicate undervaluation or specific company headwinds.
Return vs XLE: Since May 6, 2025, DVN has gained 65.8% against a gain of 68.9% for XLE.
Performance against XLE
DVN and the Energy sector fund over the same days.
Revenue and earnings
How much DVN sells, and how much of it becomes profit.
Revenue growth: Revenue grew 7.8% in FY2025 to $17.2B, from $15.9B a year earlier.
Profit margin: The net margin was 15.6% in FY2025, down from 18.5% the year before.
Profitable: DVN earned $2.7B in FY2025.
Earnings reality check
Did DVN beat what analysts expected, and how did the stock react?
Earnings record: DVN beat the analyst estimate in 3 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 4, 2026after close | $1.41 | $1.57 | +11.35% | -4.45% | +3.06% |
| May 5, 2026after close | $1.09 | $1.04 | -4.59% | -8.61% | -8.28% |
| Nov 5, 2025after close | $0.94 | $1.04 | +10.64% | +0.28% | +8.91% |
| Aug 5, 2025after close | $0.86 | $0.84 | -2.33% | +0.43% | +3.13% |
| May 6, 2025after close | $1.23 | $1.21 | -1.63% | -0.98% | +12.10% |
| Feb 18, 2025after close | $1.00 | $1.16 | +16.00% | +7.71% | +2.87% |
| Nov 5, 2024after close | $1.10 | $1.10 | +0.00% | +1.73% | -2.54% |
As of October 16, 2026, DVN has beaten the analyst EPS estimate in 3 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on August 4, 2026, came in 11.35% above the estimate and the stock moved -4.45% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 61.8, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 61.8 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of DVN
The score, the reasoning behind it, and what could move the price next.
DVN is in an uptrend: the price of $50.73 sits 12.13% above its 200-day average of $45.24 and 5.78% above its 50-day average of $47.96. Near the top of its 52-week range, the stock is 3.76% below the high of $52.71 and 61.20% above the low of $31.47. Because the 50-day average is 6.01% above the 200-day, the averages back the move instead of working against it.
The 14-day RSI of 61.8 is in the bullish zone, below the overbought line, and the MACD line is positive. The record is positive across every period shown: the price rose 15.74% over the past three months, rose 14.70% over the past six months and rose 58.38% over the past year.
Earnings beat ›
The August 4, 2026 report beat the EPS estimate by 11.35%, and the share price fell 4.45% in the first session after it.
Source: Earnings report, August 4, 2026
Rating reaffirmed ›
Barclays kept its Overweight rating on October 9, 2026.
Source: Analyst action, Barclays, October 9, 2026
- Keep an eye on the two closest levels: the 52-week high at $52.71, which sits above the price, and the 20-day EMA at $48.68, which sits below it.
- The 14-day RSI is 61.8, inside the bullish zone, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- Following the August 4, 2026 report, the share price dropped 4.45% in the first session. Even so, DVN has beaten estimates in 3 of its last 7 reports.
DVN's uptrend depends on the price holding above its 50-day average of $47.96 and its 200-day average of $45.24. A close below the 50-day would be the first sign of that trend weakening. If the price pulls back, the first level it would reach is the 20-day EMA at $48.68.
The 52-week high at $52.71 is the next level overhead. Momentum, with the RSI in the bullish zone, still backs the move.
Technical indicators
Momentum and trend for DVN, from its daily closes.
As of October 16, 2026, with DVN at $50.73, its 14-day RSI is 61.8 (showing bullish momentum without being overbought), its 50-day simple moving average is $47.96 and its 200-day is $45.24.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What DVN moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, DVN's 1-year correlation of daily returns is +0.29 with S&P 500 (SPY), +0.20 with Nasdaq 100 (QQQ), -0.05 with Bitcoin (BTC) and -0.06 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
26 of 28 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $62.00 is 22.2% above the price.More buy ratings than three months ago ›
26 of 28 rate it a buy now, against 25 of 27 three months ago.
DVN Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | Barclays | Maintains | Overweight |
| Oct 7, 2026 | UBS | Maintains | Buy |
| Oct 7, 2026 | Truist Securities | Maintains | Buy |
| Oct 2, 2026 | JP Morgan | Maintains | Overweight |
| Sep 28, 2026 | Wells Fargo | Maintains | Overweight |
| Sep 14, 2026 | Raymond James | Maintains | Strong Buy |
As of October 16, 2026, 28 Wall Street analysts cover DVN: 26 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $44.00 to $68.00, with a median of $62.00, 22.2% above the price of $50.73.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
DVN trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from DVN's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much DVN tends to move, against the market and on its own.
The long record
DVN's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.99% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 86.1%, from January 2017 to March 2020, regained by December 2021.Most 1-year holds ended higher ›
42% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $15,782, against $42,525 in the S&P 500 (SPY).
DVN Drawdowns & Recovery
As of October 16, 2026, DVN's worst peak-to-trough fall over the last 10 years with dividends reinvested was -86.1% (January 2017 to March 2020); it regained that peak by December 2021, 21 months after the low, and 42% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into DVN in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: DVN trailed the S&P 500 over this period: $15,782 against $42,525.
A $10,000 investment in DVN in October 2016 would be worth about $15,782 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to DVN, and which have not.
Strongest month, November: an average of +9.08%, up in 6 of 10 years.
Weakest month, March: an average of -2.84%, up in 6 of 10 years.
This month, October: has averaged -0.52%, up in 2 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, DVN's strongest calendar month has been November (average +9.08%, up in 6 of 10 years) and its weakest March (average -2.84%, up in 6 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in DVN, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DVN today could grow to about $14,852 by 2036 in the base case, with a 90th-percentile outcome near $112,678 and a 10th-percentile outcome around $1,958. The simulation models price only; at today's 2.21% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
DVN Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $59.43 for DVN by 2030 in the base case, from $50.73 today (1.2x over 4 years). The 10th-percentile path ends near $16.50. These are outcomes of a Monte Carlo simulation run on DVN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $27.81 | $52.78 | $100 | |
| 2028 | $22.18 | $54.91 | $136 | |
| 2029 | $18.83 | $57.12 | $173 | |
| 2030 | $16.50 | $59.43 | $214 | |
| 2031 | $14.75 | $61.82 | $259 |
Method: a lognormal simulation of DVN's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
DVN insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $200K on the open market and sold $5.9M.
As of October 16, 2026, DVN insiders reported 5 open-market sales worth $5.9M and 1 open-market purchase worth $200K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Robert Ferrall Lowe III
Officer
|
Sell | 6.8K | $344.2K |
| Sep 14, 2026 | Clay M. Gaspar
Chief Executive Officer
|
Buy | 3.9K | $199.9K |
| Sep 10, 2026 | Clay M. Gaspar
Chief Executive Officer
|
Grant | 54.0K | - |
| Jul 1, 2026 | Thomas E Jorden
Director
|
Grant | 7.7K | - |
| Jun 30, 2026 | Amanda M. Brock
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Ann G. Fox
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Jacinto J. Hernandez
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Thomas E Jorden
Director
|
Grant | 7.7K | - |
| Jun 30, 2026 | Kelt Kindick
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Karl F Kurz
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Jeffrey Earle Shellebarger
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Brent J Smolik
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Marcus A Watts
Director
|
Grant | 5.6K | - |
| Jun 30, 2026 | Valerie M Williams
Director
|
Grant | 5.6K | - |
| Jun 10, 2026 | Andrea Alexander
Officer
|
Sell | 18.0K | $841.3K |
| Jun 10, 2026 | Robert Ferrall Lowe III
Chief Technology Officer
|
Grant | 30.0K | - |
| May 15, 2026 | Thomas E Jorden
Director
|
Grant | 315.9K | - |
| May 14, 2026 | Adam M Vela
General Counsel
|
Sell | 24.3K | $1.1M |
| May 11, 2026 | Jeffrey L. Ritenour
Officer
|
Sell | 70.0K | $3.3M |
| May 7, 2026 | Andrea Alexander
Officer
|
Grant | 156.5K | - |
| May 7, 2026 | Amanda M. Brock
Director
|
Grant | 55.7K | - |
| May 7, 2026 | Gregory F Conaway
Officer
|
Grant | 18.4K | - |
| May 7, 2026 | Michael D Deshazer
Officer
|
Grant | 204.3K | - |
| May 7, 2026 | Jacinto J. Hernandez
Director
|
Grant | 6.8K | - |
| May 7, 2026 | Thomas E Jorden
Director
|
Grant | 2.6M | - |
| May 7, 2026 | Jeffrey Earle Shellebarger
Director
|
Grant | 6.5K | - |
| May 7, 2026 | Blake A Sirgo
Officer
|
Grant | 199.0K | - |
| May 7, 2026 | Adam M Vela
General Counsel
|
Grant | 154.9K | - |
| May 7, 2026 | Marcus A Watts
Director
|
Grant | 55.7K | - |
| May 7, 2026 | Shannon E. Young III
Chief Financial Officer
|
Grant | 323.5K | - |
| Feb 10, 2026 | Dennis Clarke Cameron
General Counsel
|
Grant | 23.9K | - |
| Feb 10, 2026 | Tana K Cashion
Officer
|
Grant | 15.6K | - |
| Feb 10, 2026 | Clay M. Gaspar
Chief Executive Officer
|
Grant | 68.3K | - |
| Feb 10, 2026 | Thomas Jeffrey Hellman
Officer
|
Grant | 16.6K | - |
| Feb 10, 2026 | Robert Ferrall Lowe III
Chief Technology Officer
|
Grant | 26.5K | - |
| Feb 10, 2026 | John David Raines
Officer
|
Grant | 16.6K | - |
| Feb 10, 2026 | Jeffrey L. Ritenour
Chief Financial Officer
|
Grant | 35.0K | - |
| Feb 10, 2026 | John Bennett Sherrer
Officer
|
Grant | 3.7K | - |
| Jan 27, 2026 | Dennis Clarke Cameron
General Counsel
|
Grant | 14.9K | - |
| Jan 27, 2026 | Tana K Cashion
Officer
|
Grant | 9.5K | - |
| Jan 27, 2026 | Clay M. Gaspar
Chief Executive Officer
|
Grant | 23.8K | - |
| Jan 27, 2026 | Robert Ferrall Lowe III
Chief Technology Officer
|
Grant | 2.5K | - |
| Jan 27, 2026 | John David Raines
Officer
|
Grant | 3.7K | - |
| Jan 27, 2026 | Jeffrey L. Ritenour
Chief Financial Officer
|
Grant | 21.4K | - |
| Nov 21, 2025 | Dennis Clarke Cameron
General Counsel
|
Grant | 11.4K | - |
| Oct 9, 2025 | Brent J Smolik
Director
|
Grant | 4.5K | - |
| Aug 11, 2025 | Kelt Kindick
Director
|
Sell | 7.7K | $257.1K |
| Jun 4, 2025 | Barbara M Baumann
Director
|
Grant | 7.3K | - |
| Jun 4, 2025 | John E Bethancourt
Director
|
Grant | 10.1K | - |
| Jun 4, 2025 | Ann G. Fox
Director
|
Grant | 7.3K | - |
| Jun 4, 2025 | Gennifer F. Kelly
Director
|
Grant | 7.3K | - |
| Jun 4, 2025 | Kelt Kindick
Director
|
Grant | 7.3K | - |
| Jun 4, 2025 | Karl F Kurz
Director
|
Grant | 7.3K | - |
| Jun 4, 2025 | Michael N Mears
Director
|
Grant | 7.3K | - |
| Jun 4, 2025 | Robert A Mosbacher Jr
Director
|
Grant | 7.3K | - |
| Jun 4, 2025 | Valerie M Williams
Director
|
Grant | 7.3K | - |
| May 14, 2025 | Dennis Clarke Cameron
General Counsel
|
Grant | 28.9K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.